 DANVERS, Mass.--BUSINESS WIRE--Abiomed NASDAQ:ABMD announced today that the first patient has been enrolled in PROTECT IV, a large, prospective, multi-center randomized controlled trial RCT that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation for Impella in high-risk percutaneous coronary intervention HRPCI. The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber, chief of cardiology at Asce 